Y-mAbs Therapeutics (YMAB) Scheduled to Post Earnings on Tuesday

Y-mAbs Therapeutics (NASDAQ:YMAB) is scheduled to be announcing its earnings results after the market closes on Tuesday, May 7th. Analysts expect the company to announce earnings of ($0.12) per share for the quarter. Y-mAbs Therapeutics has set its FY 2024 guidance at EPS.Persons interested in listening to the company’s earnings conference call can do so using this link.

Y-mAbs Therapeutics (NASDAQ:YMAB) last announced its earnings results on Thursday, February 29th. The company reported ($0.02) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.17. The firm had revenue of $23.36 million for the quarter, compared to the consensus estimate of $21.72 million. Y-mAbs Therapeutics had a negative net margin of 25.26% and a negative return on equity of 20.72%. On average, analysts expect Y-mAbs Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Y-mAbs Therapeutics Price Performance

Shares of YMAB stock opened at $17.15 on Friday. The firm has a 50 day moving average of $15.71 and a two-hundred day moving average of $10.92. Y-mAbs Therapeutics has a 52 week low of $4.60 and a 52 week high of $20.90.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the company. HC Wainwright lifted their target price on Y-mAbs Therapeutics from $21.00 to $22.00 and gave the company a “buy” rating in a report on Wednesday, March 6th. Canaccord Genuity Group lifted their price objective on Y-mAbs Therapeutics from $22.00 to $26.00 and gave the company a “buy” rating in a research note on Monday, March 4th. BMO Capital Markets upped their target price on shares of Y-mAbs Therapeutics from $16.00 to $26.00 and gave the stock an “outperform” rating in a research note on Monday, March 4th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $18.00 target price (up previously from $12.00) on shares of Y-mAbs Therapeutics in a report on Monday, February 12th. Two equities research analysts have rated the stock with a sell rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $16.57.

Insider Buying and Selling

In other Y-mAbs Therapeutics news, SVP Vignesh Rajah sold 1,711 shares of the firm’s stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $16.53, for a total transaction of $28,282.83. Following the transaction, the senior vice president now owns 33,889 shares of the company’s stock, valued at $560,185.17. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 21.50% of the stock is owned by company insiders.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.